Leveraging ADMET Profiling, Network Pharmacology, and Molecular Docking to Evaluate the Repurposing of Product Nkabinde for COVID-19 Treatment
Open Access
- 30 April 2026
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1022
Abstract
Background: The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, remains a significant threat to global health. This continued threat is due to the emergence of new variants, the immune system’s limited ability to respond, and the limited effectiveness of available treatments for all individuals. Therefore, leveraging drug repurposing, a fast and inexpensive way to find other drugs that have already been shown to be safe and efficacious, becomes useful. This study leverages ADMET profiling, network pharmacology, and molecular docking to evaluate the repurposing of Product Nkabinde for COVID-19 treatment. Methods: ADMET analysis involving the bioactive phytochemicals of PN was evaluated for pharmacokinetic appropriateness and drug-likeness. Using topological analysis, a network of protein–protein interactions was built to identify hub genes, and predicted compound targets were intersected with COVID-19-associated genes to find shared targets. Their biological importance was characterized using functional enrichment analysis. The binding affinities of PN phytochemicals against hub proteins and SARS-CoV-2 viral proteases (Mpro and PLpro) were assessed by molecular docking using AutoDock Vina. To confirm docking accuracy, co-crystallized ligands were redocked using Schrodinger 2022-1. The multi-target therapeutic potential of PN in COVID-19 was assessed using this integrative network pharmacology and molecular docking technique. Results: Molecular docking demonstrated that PN phytochemicals displayed robust and persistent binding affinities for both viral and host targets. Oleanolic acid showed the best affinity toward Mpro (−12.9 kcal/mol vs. −8.3 kcal/mol), while quercetin-3-O-β-D-(6′-galloyl)-glucopyranoside showed better binding to PLpro (−8.4 kcal/mol vs. −6.4 kcal/mol). Procyanidin B2 toward HCK (−10.5 vs. −7.9 kcal/mol), diosgenin toward EGFR (−9.4 vs. −8.4 kcal/mol), rutin toward SRC (−10.5 vs. −7.8 kcal/mol), and pimelea factor P2 toward PIK3R1 (−11.0 vs. −8.2 kcal/mol) all showed significantly higher affinities than their corresponding co-crystallized ligands. Furthermore, procyanidin B2 demonstrated consistent binding to STAT1 and STAT3, confirming its role in modulating immune signals. Most of the PN phytochemicals show advantageous pharmacokinetic properties, including elevated anticipated gastrointestinal absorption and adherence to Lipinski’s rule of five, signifying favorable oral bioavailability and drug-like properties. Moreover, PN exhibits a remarkable multi-target binding capacity against both SARS-CoV-2 proteases and key host signaling proteins involved in immune regulation and inflammatory responses, as determined by this integrative network pharmacology and molecular docking investigation. Conclusions: PN’s prospects as a host-directed, antiviral treatment for COVID-19 are demonstrated by its coordinated modulation of the PI3K/AKT, JAK–STAT, SRC-family kinase, EGFR, and SYK pathways. These results necessitate further experimental and clinical validation, providing a solid computational basis for repurposing PN in the treatment of COVID-19.Keywords
This publication has 114 references indexed in Scilit:
- Targeting PDGFR, EGFR, FGFR, and VEGFR: Key Receptor Tyrosine Kinases‐Driven Metabolic Reprogramming in Pulmonary Arterial HypertensionMedicinal Research Reviews, 2025
- Functional Insights Through Gene Ontology, Disease Ontology, and KEGG Pathway Enrichment2025
- The roles of macrophages and monocytes in COVID-19 Severe Respiratory SyndromeCell Insight, 2025
- Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?Antiviral Research, 2025
- The role of vasculature and angiogenesis in respiratory diseasesAngiogenesis, 2024
- Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19Reviews in Medical Virology, 2023
- A coronavirus disease 2019–vaccinated patient with phosphoinositide 3-kinase disease with mild illness after severe acute respiratory syndrome coronavirus 2 infectionAnnals of Allergy, Asthma & Immunology, 2022
- Target-based drug discovery, ADMET profiling and bioactivity studies of antibiotics as potential inhibitors of SARS-CoV-2 main protease (Mpro)VirusDisease, 2021
- PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19Human Cell, 2021
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19Cell, 2020